AVAI (Avai Bio) Additional Paid-In Capital: $3.02 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVAI Avai Bio Inc AVAI
22 GF Score
Price $0.14
! 3 Warning Signs
View Full Analysis

What is Avai Bio Additional Paid-In Capital?

Avai Bio AVAI +2.12% 22 Additional Paid-In Capital is $3.02 Mil as of Jun. 2026. GuruFocus rates AVAI with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.


Avai Bio's quarterly additional paid-in capital increased from Dec. 2025 ($2.65 Mil) to Mar. 2026 ($2.87 Mil) and increased from Mar. 2026 ($2.87 Mil) to Jun. 2026 ($3.02 Mil).

Avai Bio's annual additional paid-in capital increased from Mar. 2024 ($1.37 Mil) to Mar. 2025 ($2.39 Mil) and increased from Mar. 2025 ($2.39 Mil) to Mar. 2026 ($2.87 Mil).

Avai Bio Additional Paid-In Capital Related Terms

Avai Bio Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Avai Bio's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avai Bio Additional Paid-In Capital Chart

Avai Bio Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only 0.06 0.17 1.37 2.39 2.87

Avai Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.45 2.59 2.65 2.87 3.02
AVAI
22GF Score
Avai Bio Inc AVAI
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avai Bio Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $3.02 Mil mean?
Avai Bio (AVAI) has a Additional Paid-In Capital of $3.02 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Avai Bio and its competitors.
Is Avai Bio's Additional Paid-In Capital too high?
Avai Bio's current Additional Paid-In Capital is $3.02 Mil. Overall, Avai Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's Additional Paid-In Capital compare to IPM and CRMZ?
Avai Bio's Additional Paid-In Capital of $3.02 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Software company?
A good Additional Paid-In Capital depends on the Software industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Avai Bio and its competitors. Avai Bio's current Additional Paid-In Capital is $3.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current Additional Paid-In Capital of $3.02 Mil. The current Additional Paid-In Capital is $3.02 Mil. Avai Bio's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Avai Bio (AVAI), the current Additional Paid-In Capital is $3.02 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avai Bio Business Description

Address 5348 Vegas Drive, Las Vegas, NV, USA, 89108
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
22GF Score

Get the complete analysis for AVAI

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.14
Price